3,222 reports of this reaction
1.2% of all DENOSUMAB reports
#20 most reported adverse reaction
HYPOCALCAEMIA is the #20 most commonly reported adverse reaction for DENOSUMAB, manufactured by Amgen, Inc. There are 3,222 FDA adverse event reports linking DENOSUMAB to HYPOCALCAEMIA. This represents approximately 1.2% of all 278,448 adverse event reports for this drug.
Patients taking DENOSUMAB who experience hypocalcaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOCALCAEMIA is a less commonly reported adverse event for DENOSUMAB, but still significant enough to appear in the safety profile.
In addition to hypocalcaemia, the following adverse reactions have been reported for DENOSUMAB:
The following drugs have also been linked to hypocalcaemia in FDA adverse event reports:
HYPOCALCAEMIA has been reported as an adverse event in 3,222 FDA reports for DENOSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOCALCAEMIA accounts for approximately 1.2% of all adverse event reports for DENOSUMAB, making it a notable side effect.
If you experience hypocalcaemia while taking DENOSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.